Presented to the United States
Food and Drug Administration’s
Vaccines and Related Biological Products Advisory Committee
May 18, 2006
My name is Dr. Beth Jordan, medical director of the Association of Reproductive Health Professionals (ARHP). ARHP was founded in 1963 and is a multidisciplinary professional association with over 12,000 core and associate members, including physicians, advanced practice clinicians, researchers, and educators, all with expertise in reproductive health research or practice. ARHP and its members provide reproductive health services or education, or conduct reproductive health research. ARHP fosters research and advocacy to improve reproductive health.
ARHP is accredited by the Accreditation Council for Continuing Medical Education to provide continuing medical education to health care providers through a variety of educational programs, meetings, and publications. ARHP advocates for evidence-based research and supports the availability of, and education about, a wide range of safe, effective, and appropriate new technologies to enhance the health of all women.
On behalf of ARHP and its members, I am honored to provide comments before the FDA’s Vaccines and Related Biological Products Advisory Committee in support of the approval of the Human Papillomavirus (HPV) Recombinant Vaccine. Our support is based on the following:
- There are very few medically proven mechanisms to prevent cancer. The HPV vaccine represents a rare opportunity to prevent cervical cancer, which affects over 15,000 women in the United States each year.
- The research demonstrates that this vaccine is both safe and effective in preventing the most dangerous strains of the cancer-causing and highly infectious HPV.
- The vaccine, along with appropriate screening (including Pap tests and DNA tests), are important measures toward the eventual eradication of cervical cancer through a combined approach: prevention and early detection.
- In order to ensure the most appropriate and effective use of this product, public and provider education will be needed.
For these reasons, ARHP respectfully recommends that the FDA move forward with the approval process for the HPV vaccine. Once approved, ARHP is committed to providing the necessary education surrounding this vaccine to health care providers, patients, and parents.
I would like to thank the committee for the opportunity to present this statement of support on this important issue.